The glycolipid α -galactosylceramide (α -GalCer), which is presented by CD1d and specifically activates Vα 14 NKT cells, exerts a potent anti-metastatic effect when administered in vivo. In this study, we demonstrated that α -GalCer administration led to rapid elimination of NKT cells by apoptosis in the liver and spleen, after they produced IFN-γ and IL-4. In contrast, a more prolonged secretion of IFN-γ was observed by liver and splenic NK cells after α -GalCer administration. Cytotoxic activity of liver mononuclear cells was not augmented 3h after α -GalCer administration, but was increased at 24 h when NKT cells were mostly depleted. The α -GalCer-induced cytotoxic activity was abolished in IFN-γ -deficient and NK cell-depleted mice as well as CD1-deficient mice, suggesting that the α -Galcer-induced cytotoxicity was mainly mediated by IFN-γ -activated NK cells. While the α -GalCer-induced cytotoxicity in vitro was mostly perforin dependent, anti-metastatic effect of α -GalCer was impaired in NK cell-depleted or IFN-γ -deficient mice but not in perforin-deficient mice. Collectively, these results indicated that the anti-metastatic effect of α -GalCer is mainly mediated by NK cells, which are activated secondarily by IFN-γ produced by α -GalCer-activated NKT cells, in aperforin-independent manner.
No takes yet. Share an insight, caveat, or question.
Hayakawa et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: